Michelle Wilson
Family · Boonville, INNPI 1982053385
Payments from drug & device makers
Across 252 payments — averaging $13.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Lilly USA, LLC$268
- Novo Nordisk$197
- GSK$168
- Takeda Pharmaceuticals U.S.A., Inc.$164
- Otsuka America Pharmaceutical, Inc.$136
- plus $1K from 24 others
What the payments were for
- Food & beverage$3,331100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 106 | $1,166 |
| Lilly USA, LLC | 19 | $268 |
| Novo Nordisk | 13 | $197 |
| GSK | 10 | $168 |
| Takeda Pharmaceuticals U.S.A., Inc. | 11 | $164 |
| Otsuka America Pharmaceutical, Inc. | 8 | $136 |
| Pfizer | 7 | $112 |
| Corium, LLC | 8 | $101 |
| Amgen | 6 | $96 |
| Axsome Therapeutics, Inc. | 5 | $93 |
| Sunovion Pharmaceuticals Inc. | 10 | $91 |
| Alkermes, Inc. | 4 | $72 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 4 | $68 |
| Supernus Pharmaceuticals, Inc. | 5 | $65 |
| Intuitive Surgical | 5 | $64 |
| Boehringer Ingelheim | 4 | $63 |
| Biohaven Pharmaceutical Holding Company Ltd. | 4 | $59 |
| Ironshore Pharmaceuticals Inc. | 3 | $54 |
| AstraZeneca | 4 | $52 |
| Biohaven Pharmaceuticals, Inc. | 3 | $40 |
| Medtronic | 2 | $35 |
| Lundbeck LLC | 2 | $32 |
| Genentech USA, Inc. | 2 | $28 |
| Novartis | 1 | $20 |
| Exact Sciences | 1 | $20 |
| Astellas Pharma US Inc | 1 | $17 |
| Sanofi-aventis U.S. LLC | 1 | $15 |
| Amarin Pharma, Inc. | 1 | $12 |
| Organon | 1 | $12 |
| Sumitomo Pharma America, Inc. | 1 | $11 |
How this compares
$3,331 in reported general payments places this provider in the 85th percentile of 4,392 family providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 84 | $110,533 |
| MounjaroTirzepatide | 55 | $56,721 |
| RexultiBrexpiprazole | 37 | $54,760 |
| Tresiba Flextouch U-200Insulin Degludec | 30 | $30,923 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 28 | $22,113 |
| JardianceEmpagliflozin | 14 | $19,310 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 24 | $16,421 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 24 | $11,288 |
| LinzessLinaclotide | 18 | $10,648 |
| Tresiba Flextouch U-100Insulin Degludec | 16 | $9,071 |
| ShingrixVaricella-Zoster Ge/As01b/Pf | 26 | $5,706 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 11 | $3,515 |
| ArexvyRsvpref3 Antigen/As01e/Pf | 11 | $3,478 |
| Desvenlafaxine Succinate ErDesvenlafaxine Succinate | 21 | $1,721 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 18 | $1,640 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $197 | $110,53384 claims |
| Lilly USA, LLCMounjaro | $268 | $56,72155 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $136 | $54,76037 claims |
| GSKTrelegy Ellipta, Shingrix, Arexvy | $168 | $31,29765 claims |
| Boehringer IngelheimJardiance, Stiolto Respimat | $63 | $30,59838 claims |
| AstraZenecaBreztri Aerosphere | $52 | $16,42124 claims |
| AbbVieLinzess | $1,166 | $10,64818 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 4,392 family providers in Indiana.
Other family in Boonville
- Rebecca NanceBoonville$41K
- Tina SizemoreIndianapolis$888K
- Kathalene Keller RineyEvansville$383K
- Robin AndersonPortage$333K
- Marla MosesIndianapolis$142K
- Justin BrownFort Wayne$142K
- Lacey MatheisEvansville$139K
- Myra SikwataHobart$131K
- Elizabeth JohnsonEvansville$108K
- Beverly MaugerFt Wayne$94K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.